Pralatrexate induced durable response in a relapsed/refractory peripheral T-cell lymphoma patient with a history of autologous stem cell transplantation: Case report of a patient followed-up over 3 years under pralatrexate treatment

摘要

Rationale: Relapsed or refractory peripheral T-cell lymphomas are aggressive diseases. Pralatrexate is an antimetabolite. Hereby, we are reporting a pralatrexate induced durable response in a relapsed/refractory peripheral T-Cell lymphoma patient with a history of autologous stem cell transplantation. Patient concerns: A male patient born in February 1947 was diagnosed with lymphoma based on his cervical lymph node excisional biopsy. Diagnoses: He was diagnosed with PTCL-NOS on February 19, 2013. Interventions: The patient received 6 cycles of CHOP (Cyclophosphamide, doxorubicine, vincristine, methylprednisolone) chemotherapy, which achieved a complete remission. The patient underwent autologous stem cell transplantation in December 2013. After relapse was detected in the third month of the transplantation, the patient was treated with 2 cycles of ViGePP (vinorelbine, gemcitabine, procarbazine, prednisone/ methylprednisolone) chemotherapy. The patient was considered refractory to treatment after the ViGePP chemotherapy, and he was given brentuximab vedotin. Once a full response to treatment was achieved after 2 cycles, the patient received 6 cycles of brentuximab vedotin treatment. After 6 cycles, a skin biopsy was performed and the patient was diagnosed with relapsed/refractory PTCL-NOS . Pralatrexate therapy was then started on February 1, 2016 at a dose of 30 mg/msup xmlns:mrws="http://webservices.ovid.com/mrws/1.0"2/sup once weekly for 6 weeks in 7-week cycles. Outcomes: The patient responded to pralatrexate treatment. And he has been under pralatrexate treatment over 3 years. Lessons: Pralatrexate should also be kept in mind as a treatment alternative in relapsed or refractory peripheral T-cell lymphoma patients.